Activation of the interferon pathway in peripheral blood of patients with Sjögren's syndrome

Journal of Rheumatology

Volumn 38, Issue 2, 2011, Pages 310-316

  Kimoto, Osamu ^a   Sawada, Jin ^a   Shimoyama, Kumiko ^a   Suzuki, Daisuke ^a   Nakamura, Satoki ^a   Hayashi, Hideharu ^a   Ogawa, Noriyoshi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Interferons; Microarray analysis; Polymerase chain reaction; Sj gren's syndrome

Indexed keywords

ALPHA INTERFERON INDUCIBLE PROTEIN 27; ANTINUCLEAR ANTIBODY; BETA 2 MICROGLOBULIN; IMMUNOGLOBULIN G; INTERFERON; INTERLEUKIN 2 RECEPTOR; PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; DNA MICROARRAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOPATHOGENESIS; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SJOEGREN SYNDROME; SYMPTOM;

AGED; FEMALE; GENE EXPRESSION; HUMANS; INTERFERONS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SJOGREN'S SYNDROME; STATISTICS, NONPARAMETRIC;

EID: 79551707889     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100486     Document Type: Article

References (34)

1. Anaya JM, Delgado-Vega AM, Castiblanco J. Genetic basis of Sjögren's syndrome. How strong is the evidence? Clin Dev Immunol 2006;13:209-22.
2. Fox RI. Sjögren's syndrome. Lancet 2005;366:321-31.
3. Hu S, Zhou M, Jiang J, Wang J, Elashoff D, Gorr S, et al. Systems biology analysis of Sjögren's syndrome and mucosa-associated lymphoid tissue lymphoma in parotid glands. Arthritis Rheum 2009;60:81-92.
4. Takei M, Shiraiwa H, Azuma T, Hayashi Y, Seki N, Sawada S. The possible etiopathogenic genes of Sjögren's syndrome. Autoimmun Rev 2005;4:479-84.
5. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100:2610-5.
6. Wenzel J, Zahn S, Bieber T, Tuting T. Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus. Arch Dermatol Res 2009;301:83-6.
7. Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007;56:3784-92. (Pubitemid 350100711)
8. Ishii T, Onda H, Tanigawa A, Ohshima S, Fujiwara H, Mima T, et al. Isolation and expression profiling of genes upregulated in the peripheral blood cells of systemic lupus erythematosus patients. DNA Res 2005;12:429-39.
9. Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2951-62.
10. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23. (Pubitemid 36350866)
11. Wakamatsu E, Nakamura Y, Matsumoto I, Goto D, Ito S, Tsutsumi A, et al. DNA microarray analysis of labial salivary glands of patients with Sjögren's syndrome. Ann Rheum Dis 2007;66:844-5. (Pubitemid 46846717)
12. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects. Arthritis Rheum 2005;52:1534-44. (Pubitemid 40663945)
13. Perez P, Anaya JM, Aguilera S, Urzua U, Munroe D, Molina C, et al. Gene expression and chromosomal location for susceptibility to Sjögren's syndrome. J Autoimmun 2009;33:99-108.
14. Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci USA 2006;103:2770-5.
15. Hu S, Wang J, Meijer J, Ieong S, Xie Y, Yu T, et al. Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. Arthritis Rheum 2007;56:3588-600.
16. Zheng L, Zhang Z, Yu C, Tu L, Zhong L, Yang C. Association between IFN-alpha and primary Sjögren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107:e12-8.
17. Bave U, Nordmark G, Lovgren T, Ronnelid J, Cajander S, Eloranta ML, et al. Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005;52:1185-95. (Pubitemid 40530126)
18. Takashi F, Susumu S, Nobuyuki M, Yoshio H, Kazuo T. Revised Japanese criteria for Sjögren's syndrome (1999): availability and validity. Mod Rheumatol 2004;14:425-34.
19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
20. Spadaro A, Riccieri V, Benfari G, Scillone M, Taccari E. Soluble interleukin-2 receptor in Sjögren's syndrome: relation to main serum immunological and immunohistochemical parameters. Clin Rheumatol 2001;20:319-23. (Pubitemid 32936793)
21. Maddali Bongi S, Campana G, D'Agata A, Palermo C, Bianucci G. The diagnosis value of beta 2-microglobulin and immunoglobulins in primary Sjögren's syndrome. Clin Rheumatol 1995;14:151-6.
22. Manoussakis MN, Papadopoulos GK, Drosos AA, Moutsopoulos HM. Soluble interleukin 2 receptor molecules in the serum of patients with autoimmune diseases. Clin Immunol Immunopathol 1989;50:321-32.
23. Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, Drexhage HA, Versnel MA. Systemic increase in type I interferon activity in Sjögren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol 2008;38:2024-33.
24. Delgado-Vega AM, Castiblanco J, Gomez LM, Diaz-Gallo LM, Rojas-Villarraga A, Anaya JM. Bcl-2 antagonist killer 1 (BAK1) polymorphisms influence the risk of developing autoimmune rheumatic diseases in women. Ann Rheum Dis;69:462-5.
25. Wakamatsu E, Matsumoto I, Yasukochi T, Naito Y, Goto D, Mamura M, et al. Overexpression of phosphorylated STAT-1 alpha in the labial salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 2006;54:3476-84. (Pubitemid 44737159)
26. Ogawa N, Kawanami T, Shimoyama K, Ping L, Sugai S. Expression of interferon-inducible T cell alpha chemoattractant (CXCL11) in the salivary glands of patients with Sjögren's syndrome. Clin Immunol 2004;112:235-8. (Pubitemid 39078698)
27. Ogawa N, Ping L, Zhenjun L, Takada Y, Sugai S. Involvement of the interferon gamma-induced T cell-attracting chemokines, interferon-gamma- inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjögren's syndrome. Arthritis Rheum 2002;46:2730-41.
28. Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009;60:1785-96.
29. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001;14:461-70.
30. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002;3:822-9.
31. Lavie F, Miceli-Richard C, Quillard J, Roux S, Leclerc P, Mariette X. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome. J Pathol 2004;202:496-502.
32. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664-71.
33. Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC Jr. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005;64:1692-7.
34. Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK. Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis Rheum 2007;56:3995-4004.